Biogen Hopes Alzheimer’s Drug Mired in Controversy Earns FDA Nod

Jeffrey Borghoff was just 51 when he received a diagnosis of early-stage Alzheimer’s disease. Shortly thereafter, he retired from his job as a software developer and went on disability. He also quickly enrolled in a trial for an experimental Biogen Inc. drug to remove an aberrant amyloid protein from his brain that researchers believe is tied to reduction in memory and brain function in Alzheimer’s patients. Since then, with the exception of a brief interruption, he’s been getting monthly infusions of the medicine, named aducanumab, which he credits with slowing his cognitive decline. Now 57, Borghoff can’t drive because he confuses red and green lights, but he can still cook and take walks with his wife, Kimberly, and their dog. His life, he says, is full.

Now Borghoff is steeling himself: The U.S. Food and Drug Administration is set to rule soon on aducanumab, which has already been rejected by an FDA advisory panel of medical experts. The FDA may also reject the drug, requiring years of additional study. That could eventually force him to search for a trial of a different treatment—something that takes time that many patients simply don’t have.